The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set

doi:10.3899/jrheum.190122

. 2019 Jun:95:33-37.

doi: 10.3899/jrheum.190122.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set

Ying Ying Leung^{1

2}, Ana-Maria Orbai^{3

4}, Alexis Ogdie^{3

4}, Laura C Coates^{3

4}, Maarten de Wit^{3

4}, Kristina Callis Duffin^{3

4}, Lihi Eder^{3

4}, Dafna D Gladman^{3

4}, Niti Goel^{3

4}, Philip J Mease^{3

4}, Vibeke Strand^{3

4}, Oliver FitzGerald^{3

4}, William Tillett^{3

4}

Affiliations

¹ From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland. katyccc@hotmail.com.
² Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; M. de Wit, PhD, Patient Research Partner, Amsterdam University Medical Centre, Department of Medical Humanities; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Chief Medical Officer, Kezar Life Sciences, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; V. Strand, MD, Biopharmaceutical Consultant, Portola Valley, California; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath. katyccc@hotmail.com.
³ From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.
⁴ Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; M. de Wit, PhD, Patient Research Partner, Amsterdam University Medical Centre, Department of Medical Humanities; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Chief Medical Officer, Kezar Life Sciences, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; V. Strand, MD, Biopharmaceutical Consultant, Portola Valley, California; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath.

PMID: 31154402
DOI: 10.3899/jrheum.190122

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set

Ying Ying Leung et al. J Rheumatol Suppl. 2019 Jun.

. 2019 Jun:95:33-37.

doi: 10.3899/jrheum.190122.

Authors

Affiliations

¹ From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland. katyccc@hotmail.com.
² Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; M. de Wit, PhD, Patient Research Partner, Amsterdam University Medical Centre, Department of Medical Humanities; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Chief Medical Officer, Kezar Life Sciences, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; V. Strand, MD, Biopharmaceutical Consultant, Portola Valley, California; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath. katyccc@hotmail.com.
³ From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.
⁴ Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; M. de Wit, PhD, Patient Research Partner, Amsterdam University Medical Centre, Department of Medical Humanities; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Chief Medical Officer, Kezar Life Sciences, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; V. Strand, MD, Biopharmaceutical Consultant, Portola Valley, California; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath.

PMID: 31154402
DOI: 10.3899/jrheum.190122

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group reported at the 2018 GRAPPA annual meeting on the outcome of the OMERACT 2018 Conference in Terrigal, Australia. The working group presented the endorsement of the 66/68 joint count for the assessment of peripheral arthritis and the provisional endorsement of the PsA Impact of Disease 12 questionnaire for the assessment of PsA-specific health-related quality of life in PsA randomized controlled trials and observational studies. In this report, the group presents its plan to seek OMERACT endorsement for outcome measures that address the domains of MSK disease activity for enthesitis and dactylitis, physical function, fatigue, and structural damage following the OMERACT Filter 2.1 methodology.

Keywords: GRAPPA; OMERACT; OUTCOME MEASURES; PSORIASIS; PSORIATIC ARTHRITIS.

PubMed Disclaimer

Cited by

Disease activity indices in psoriatic arthritis: current and evolving concepts.
Gialouri CG, Fragoulis GE. Gialouri CG, et al. Clin Rheumatol. 2021 Nov;40(11):4427-4435. doi: 10.1007/s10067-021-05774-9. Epub 2021 May 18. Clin Rheumatol. 2021. PMID: 34003419 Review.
Critical importance of patient-reported outcomes for a comprehensive assessment of psoriatic arthritis patients.
Lo Monaco M, Mallaci Bocchio R, Natoli G, Giardina A, Cangemi I, Scibetta S, Argano C, Corrao S. Lo Monaco M, et al. Front Med (Lausanne). 2024 Jan 16;10:1332432. doi: 10.3389/fmed.2023.1332432. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38293304 Free PMC article.
Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis.
Leung YY, Orbai AM, Ogdie A, Hojgaard P, Holland R, Goel N, Chau J, Coates LC, Strand V, Gladman DD, Mease PJ, Christensen R, Tillett W. Leung YY, et al. J Rheumatol. 2021 Jan 1;48(1):58-66. doi: 10.3899/jrheum.191119. Epub 2020 Feb 1. J Rheumatol. 2021. PMID: 32007934 Free PMC article.
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes.
Nash P, Dutz JP, Peterson S, Patel BP, Eaton K, Shawi M, Zazzetti F, Wei JC. Nash P, et al. BMJ Open. 2023 Nov 8;13(11):e062306. doi: 10.1136/bmjopen-2022-062306. BMJ Open. 2023. PMID: 37940157 Free PMC article.
OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF.
Leung YY, Orbai AM, Hojgaard P, Holland R, Mathew AJ, Goel N, Chau J, Tillett W, Lindsay C, Ogdie A, Coates LC, Gladman DD, Christensen R, Mease P, Strand V. Leung YY, et al. Semin Arthritis Rheum. 2021 Oct;51(5):1117-1124. doi: 10.1016/j.semarthrit.2021.07.014. Epub 2021 Jul 24. Semin Arthritis Rheum. 2021. PMID: 34392975 Free PMC article.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set

Affiliations

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set

Authors

Affiliations

Abstract

Similar articles

Cited by

MeSH terms

LinkOut - more resources

Medical

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

MeSH terms

Related information

LinkOut - more resources

Medical

Research Materials

Miscellaneous